// App-Quantinova.ai

3557 : A phase I/II trial of combined BRAF and EGFR inhibition in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal (mCRC): The EViCT (Erlotinib and Vemurafenib in Combination Trial) study.

Researchers

Presenter

  • Jayesh Desai

Principal Investigators

  • Ben Markman

  • Sumitra Ananda

  • Niall C. Tebbutt

  • Michael Michael

  • Benjamin J. Solomon

  • Grant A. McArthur

  • Jeanne Tie

  • Peter Gibbs

  • David Ritchie

  • Rachel Koldej

  • Alan Herschtal

  • Ruth Columbus

  • David M. Ashley

  • Joanne Lundy

  • Edmond Michael Kwan

  • Paul Michael Waring

  • Ben Tran

Medical Centers

  • Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, Australia

  • Monash Medical Centre, Melbourne, Australia

  • Wetsern Health, Foostcray, Australia

  • Austin Health, Melbourne, Australia

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia

  • Walter and Eliza Hall Institute of Medical Research, Parkville, Australia

  • Walter and Eliza Hall Institute of Medical Research, Parkville, Australia

  • Royal Melbourne Hospital, Melbourne, Australia

  • Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, Australia

  • Andrew Love Cancer Centre, Geelong, Australia

  • Royal Melbourne Hospital, Parkville, Australia

  • University of Melbourne, Victoria, Australia

  • Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, Australia

Locations

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Gastroenterology (GU)

Disease

  • N/A

Biomarkers

  • B-Raf proto-oncogene, serine/threonine kinase

  • Epidermal growth factor receptor

  • Circulating DNA

Drug/Treatment

  • Vemurafenib

  • Erlotinib hydrochloride

Outcome

  • Unknown

Study Design

  • Pharmacodynamics

  • Simon'S Two Stage Design

  • Dose Escalation

  • Cohort

Phase

  • I/II

Study Id's

  • ACTRN12614000486628

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved